Adam T Whaley-Connell

List of Publications by Year
in descending order

238	10,645	31949 53	40954 93
papers	citations	h-index	g-index

250	250	250	13465
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cystamine reduces vascular stiffness in Western diet-fed female mice. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 322, H167-H180.	1.5	7
2	Targeting mineralocorticoid receptors in diet-induced hepatic steatosis and insulin resistance. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2022, 322, R253-R262.	0.9	6
3	Inhibition of sphingomyelinase attenuates diet â€“ Induced increases in aortic stiffness. Journal of Molecular and Cellular Cardiology, 2022, 167, 32-39.	0.9	6
4	Mineralocorticoid Receptor in Myeloid Cells Mediates Angiotensin II-Induced Vascular Dysfunction in Female Mice. Frontiers in Physiology, 2021, 12, 588358.	1.3	4
5	DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice. American Journal of Physiology - Renal Physiology, 2021, 320, F505-F517.	1.3	7
6	Renal resistive index as a novel biomarker for cardiovascular and kidney risk reduction in type II diabetes. Journal of Clinical Hypertension, 2020, 22, 231-233.	1.0	3
7	Endothelial sodium channel activation promotes cardiac stiffness and diastolic dysfunction in Western diet fed female mice. Metabolism: Clinical and Experimental, 2020, 109, 154223.	1.5	13
8	Western diet induces renal artery endothelial stiffening that is dependent on the epithelial Na⁺ channel. American Journal of Physiology - Renal Physiology, 2020, 318, F1220-F1228.	1.3	13
9	Endothelial sodium channel (EnNaC) activation contributes to mineralocorticoid receptormediated increases in coronary artery and cardiac fibrosis/stiffness leading to diastolic dysfunction in obesity. FASEB Journal, 2020, 34, 1-1.	0.2	0
10	Epithelial sodium channels in endothelial cells mediate diet-induced endothelium stiffness and impaired vascular relaxation in obese female mice. Metabolism: Clinical and Experimental, 2019, 99, 57-66.	1.5	40
11	Utility of obesity and metabolic dyslipidemia (a nonâ€insulin based determinate of the metabolic) Tj ETQq1 1 0.784314 rgBT /Overloc 2019, 21, 1071-1074.	1.0	6
12	Diet-Induced Obesity Promotes Kidney Endothelial Stiffening and Fibrosis Dependent on the Endothelial Mineralocorticoid Receptor. Hypertension, 2019, 73, 849-858.	1.3	41
13	Insulin Resistance and the Metabolic Syndrome in Kidney Disease (e.g., the Cardiorenal Metabolic) Tj ETQq1 1 0.784314 rgBT /Overlo		0
14	Sexual Dimorphism in Obesity-Associated Endothelial ENaC Activity and Stiffening in Mice. Endocrinology, 2019, 160, 2918-2928.	1.4	22
15	Deficiency of IL12p40 (Interleukin 12 p40) Promotes Ang II (Angiotensin II)â€“Induced Abdominal Aortic Aneurysm. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 212-223.	1.1	34
16	SAT-LB011 Role of Endothelium Epithelial Sodium Channel in Arterial Stiffness. Journal of the Endocrine Society, 2019, 3, .	0.1	0
17	Insulin Resistance in Kidney Disease: Is There a Distinct Role Separate from That of Diabetes or Obesity. CardioRenal Medicine, 2018, 8, 41-49.	0.7	65
18	Diabetes and Hypertension: Clinical Update. American Journal of Hypertension, 2018, 31, 515-521.	1.0	16

#	Article	IF	Citations
19	Treatment of Diabetic Kidney Disease With Hypertension Control and Renin Angiotensin System Inhibition. Advances in Chronic Kidney Disease, 2018, 25, 158-165.	0.6	6
20	Enhanced endothelium epithelial sodium channel signaling prompts left ventricular diastolic dysfunction in obese female mice. Metabolism: Clinical and Experimental, 2018, 78, 69-79.	1.5	35
21	Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia, 2018, 61, 21-28.	2.9	501
22	Arterial Stiffness in Hypertension: an Update. Current Hypertension Reports, 2018, 20, 72.	1.5	77
23	The Role of Insulin Resistance in the Cardiorenal Syndrome. , 2018, , 117-124.		0
24	Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management. , 2018, 191, 1-22.		100
25	Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovascular Diabetology, 2017, 16, 9.	2.7	205
26	Obesity and kidney disease: from population toÂbasic science and the search for new therapeuticÂtargets. Kidney International, 2017, 92, 313-323.	2.6	93
27	Uric acid promotes vascular stiffness, maladaptive inflammatory responses and proteinuria in western diet fed mice. Metabolism: Clinical and Experimental, 2017, 74, 32-40.	1.5	49
28	Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice. Cardiovascular Diabetology, 2017, 16, 61.	2.7	58
29	Amiloride Improves Endothelial Function and Reduces Vascular Stiffness in Female Mice Fed a Western Diet. Frontiers in Physiology, 2017, 8, 456.	1.3	37
30	Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules. International Journal of Molecular Sciences, 2016, 17, 780.	1.8	29
31	Blood Pressureâ€"Related Outcomes in a Diabetic Population. Hypertension, 2016, 68, 34-35.	1.3	5
32	Metabolic Control of Blood Pressure Variability in Humans. Journal of Clinical Hypertension, 2016, 18, 25-26.	1.0	2
33	Novel therapeutics in hypertension and kidney disease. Current Opinion in Nephrology and Hypertension, 2015, 24, 401-402.	1.0	0
34	Two-Dimensional Zymography Differentiates Gelatinase Isoforms in Stimulated Microglial Cells and in Brain Tissues of Acute Brain Injuries. PLoS ONE, 2015, 10, e0123852.	1.1	10
35	Cardiorenal Metabolic Syndrome and Diabetes in African Americans: Adding to the Risk of Hypertension. , 2015, , 137-150.		0
36	Low-Dose Mineralocorticoid Receptor Blockade Prevents Western Dietâ€"Induced Arterial Stiffening in Female Mice. Hypertension, 2015, 66, 99-107.	1.3	125

#	Article	IF	Citations
37	Obesity and Insulin Resistance in Resistant Hypertension: Implications for the Kidney. Advances in Chronic Kidney Disease, 2015, 22, 211-217.	0.6	51
38	Secondary Hypertension: Beginnings and Transitions. Advances in Chronic Kidney Disease, 2015, 22, 177-178.	0.6	0
39	Mineralocorticoid and Apparent Mineralocorticoid Syndromes of Secondary Hypertension. Advances in Chronic Kidney Disease, 2015, 22, 185-195.	0.6	14
40	Uric Acid Promotes Left Ventricular Diastolic Dysfunction in Mice Fed a Western Diet. Hypertension, 2015, 65, 531-539.	1.3	114
41	BP and Renal Outcomes in Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2159-2169.	2.2	48
42	Endothelial Mineralocorticoid Receptor Deletion Prevents Diet-Induced Cardiac Diastolic Dysfunction in Females. Hypertension, 2015, 66, 1159-1167.	1.3	111
43	Hypertension Management in Diabetic Kidney Disease. Diabetes Spectrum, 2015, 28, 175-180.	0.4	26
44	BP Targets in Older Adults with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1501-1503.	2.2	0
45	Prevention of Obesity-Induced Renal Injury in Male Mice by DPP4 Inhibition. Endocrinology, 2014, 155, 2266-2276.	1.4	46
46	Educational programs improve the preparation for dialysis and survival of patients with chronic kidney disease. Kidney International, 2014, 85, 686-692.	2.6	68
47	Implications for Glucose Measures in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes, 2014, 63, 45-47.	0.3	7
48	DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity, 2014, 22, 2172-2179.	1.5	62
49	Fructose and Uric Acid: Is There a Role in Endothelial Function?. Current Hypertension Reports, 2014, 16, 434.	1.5	45
50	The Use and Interpretation of Troponin in <scp>ESRD</scp> Patients. Seminars in Dialysis, 2014, 27, 545-547.	0.7	3
51	Diabetic Kidney Disease: A Report From an ADA ConsensusÂConference. American Journal of Kidney Diseases, 2014, 64, 510-533.	2.1	439
52	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. Diabetes Care, 2014, 37, 2864-2883.	4.3	781
53	Basic science. Journal of the American Society of Hypertension, 2014, 8, 604-606.	2.3	32
54	Salt Loading Promotes Kidney Injury via Fibrosis in Young Female Ren2 Rats. CardioRenal Medicine, 2014, 4, 43-52.	0.7	10

#	Article	IF	Citations
55	Chronic Kidney Disease and Cardiovascular Risk. Oxidative Stress in Applied Basic Research and Clinical Practice, 2014, , 49-61.	0.4	0
56	Obesity and Heart Failure as a Mediator of the Cerebrorenal Interaction. Contributions To Nephrology, 2013, 179, 15-23.	1.1	9
57	Type 2 Diabetes in Older People; The Importance of Blood Pressure Control. Current Cardiovascular Risk Reports, 2013, 7, 233-237.	0.8	8
58	Advances in CKD Detection and Determination of Prognosis: Executive Summary of the National Kidney Foundationâ€"Kidney Early Evaluation Program (KEEP) 2012 Annual Data Report. American Journal of Kidney Diseases, 2013, 61, S1-S3.	2.1	15
59	Hypertension and Diabetes Mellitus. , 2013, , 313-319.		0
60	Therapy of obese patients with cardiovascular disease. Current Opinion in Pharmacology, 2013, 13, 200-204.	1.7	11
61	The Synergistic Relationship Between Estimated GFR and Microalbuminuria in Predicting Long-term Progression to ESRD or Death in Patients With Diabetes: Results From the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2013, 61, S12-S23.	2.1	72
62	Association of Race and Body Mass Index With ESRD and Mortality in CKD Stages 3-4: Results From the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2013, 61, 404-412.	2.1	42
63	Association Between Lack of Health Insurance and Risk of Death and ESRD: Results From the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2013, 61, S24-S32.	2.1	51
64	Salt loading exacerbates diastolic dysfunction and cardiac remodeling in young female Ren2 rats. Metabolism: Clinical and Experimental, 2013, 62, 1761-1771.	1.5	13
65	Renin Inhibition and AT1R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling. Metabolism: Clinical and Experimental, 2013, 62, 861-872.	1.5	20
66	Diabetic Kidney Disease and the Cardiorenal Syndrome. Endocrinology and Metabolism Clinics of North America, 2013, 42, 789-808.	1.2	33
67	Risk Factors for ESRD in Individuals With Preserved Estimated GFR With and Without Albuminuria: Results From the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2013, 61, S4-S11.	2.1	33
68	Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II. Molecular and Cellular Endocrinology, 2013, 378, 53-58.	1.6	19
69	Liquid meal composition, postprandial satiety hormones, and perceived appetite and satiety in obese women during acute caloric restriction. European Journal of Endocrinology, 2013, 168, 593-600.	1.9	15
70	Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats. Endocrinology, 2013, 154, 2501-2513.	1.4	86
71	To <scp>RAS</scp> or Not to <scp>RAS</scp>? The Evidence for and Cautions with Reninâ€Angiotensin System Inhibition in Patients with Diabetic Kidney Disease. Pharmacotherapy, 2013, 33, 496-514.	1.2	23
72	No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney International, 2013, 84, 989-997.	2.6	54

#	Article	IF	Citations
73	DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes. CardioRenal Medicine, 2013, 3, 48-56.	0.7	48
74	Angiotensin type 1 receptor resistance to blockade in the opossum proximal tubule cell due to variations in the binding pocket. American Journal of Physiology - Renal Physiology, 2013, 304, F1105-F1113.	1.3	5
75	Novel interventions for resistant hypertension. Current Opinion in Nephrology and Hypertension, 2013, 22, 503.	1.0	0
76	Metabolic Impact of Adding a Thiazide Diuretic to Captopril. Hypertension, 2013, 61, 765-766.	1.3	0
77	Obesity-Related Alterations in Cardiac Lipid Profile and Nondipping Blood Pressure Pattern during Transition to Diastolic Dysfunction in Male db/db Mice. Endocrinology, 2013, 154, 159-171.	1.4	46
78	The Association between Parathyroid Hormone Levels and Hemoglobin in Diabetic and Nondiabetic Participants in the National Kidney Foundation's Kidney Early Evaluation Program. CardioRenal Medicine, 2013, 3, 120-127.	0.7	9
79	Enhanced coronary vasoconstriction in western dietâ€induced obesity is associated with alterations in NHE1, SERCA2a and 3. FASEB Journal, 2013, 27, lb660.	0.2	0
80	Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H2341-H2351.	1.5	50
81	Early Treatment With Olmesartan Prevents Juxtamedullary Glomerular Podocyte Injury and the Onset of Microalbuminuria in Type 2 Diabetic Rats. American Journal of Hypertension, 2012, 25, 604-611.	1.0	38
82	Over-nutrition contributes to tubulointerstitial fibrosis by targeting nutrient-sensing kinases. Cell Cycle, 2012, 11, 831-832.	1.3	3
83	The Association of Parathyroid Hormone with ESRD and Pre-ESRD Mortality in the Kidney Early Evaluation Program. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4414-4421.	1.8	10
84	Initial Choice of Antihypertensive on Long-Term Cardiovascular Outcomes in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 884-886.	2.2	0
85	Mineralocorticoid Receptor-Dependent Proximal Tubule Injury Is Mediated by a Redox-Sensitive mTOR/S6K1 Pathway. American Journal of Nephrology, 2012, 35, 90-100.	1.4	31
86	The kaliuretic impact of cicletanine compared to hydrochlorothiazide. Journal of Hypertension, 2012, 30, 691-692.	0.3	0
87	Regulation of Overnutrition-Induced Cardiac Inflammatory Mechanisms by nebivolol. CardioRenal Medicine, 2012, 2, 225-233.	0.7	16
88	Novel role for the incretins in blood pressure regulation. Current Opinion in Nephrology and Hypertension, 2012, 21, 463-468.	1.0	11
89	A Decade After the KDOQI CKD Guidelines: Impact on the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2012, 60, 692-693.	2.1	7
90	Awareness of Kidney Disease and Relationship to End-stage Renal Disease and Mortality. American Journal of Medicine, 2012, 125, 661-669.	0.6	53

#	Article	IF	Citations
91	Dysglycemia but not lipids is associated with abnormal urinary albumin excretion in diabetic kidney disease: a report from the Kidney Early Evaluation Program (KEEP). BMC Nephrology, 2012, 13, 104.	0.8	9
92	Hypertension in Chronic Kidney Disease. , 2012, , 35-50.		0
93	Predictors of Kidney Disease in Diabetic, Hypertensive Patients. , 2012, , 107-119.		0
94	Diabetic Vascular Disease. , 2012, , 1321-1328.		0
95	The Role of Insulin Resistance in the Cardiorenal Syndrome. , 2012, , 137-144.		0
96	Insulin Resistance and the Autonomic Nervous System. , 2012, , 307-312.		6
97	Oxidative Stress in the Cardiorenal Metabolic Syndrome. Current Hypertension Reports, 2012, 14, 360-365.	1.5	50
98	Associations Between Access to Care and Awareness of CKD. American Journal of Kidney Diseases, 2012, 59, S16-S23.	2.1	29
99	Access to Health Care Among Adults Evaluated for CKD: Findings From the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2012, 59, S5-S15.	2.1	39
100	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Annual Data Report 2011: Executive Summary. American Journal of Kidney Diseases, 2012, 59, S1-S4.	2.1	10
101	Physician Utilization, Risk-Factor Control, and CKD Progression Among Participants in the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2012, 59, S24-S33.	2.1	27
102	Association of Physician Care With Mortality in Kidney Early Evaluation Program (KEEP) Participants. American Journal of Kidney Diseases, 2012, 59, S34-S39.	2.1	8
103	Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. Regulatory Peptides, 2012, 176, 36-44.	1.9	15
104	Comparison of CKD Awareness in a Screening Population Using the Modification of Diet in Renal Disease (MDRD) Study and CKD Epidemiology Collaboration (CKD-EPI) Equations. American Journal of Kidney Diseases, 2011, 57, S17-S23.	2.1	31
105	Hypertension in the High-Cardiovascular-Risk Populations. International Journal of Hypertension, 2011, 2011, 1-3.	0.5	6
106	Ask the Experts: How can the National Kidney Foundationâ€™s Kidney Early Evaluation Program help to prevent/manage kidney disease in diabetic patients?. Diabetes Management, 2011, 1, 365-368.	0.5	0
107	Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. Metabolism: Clinical and Experimental, 2011, 60, 1757-1766.	1.5	21
108	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Risk Factors for and Complications of CKD and Mortality in the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2011, 57, S9-S16.	2.1	116

#	Article	IF	Citations
109	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Prevalence of and Risk Factors for Diabetes Mellitus in CKD in the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2011, 57, S24-S31.	2.1	28
110	Sustainable Community-Based CKD Screening Methods Employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2011, 57, S4-S8.	2.1	25
111	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Annual Data Report 2010: Executive Summary. American Journal of Kidney Diseases, 2011, 57, S1-S3.	2.1	8
112	Resistant Hypertension in the High-Risk Metabolic Patient. Current Diabetes Reports, 2011, 11, 41-46.	1.7	19
113	Cardiovascular Disease in Chronic Kidney Disease: Data from the Kidney Early Evaluation Program (KEEP). Current Diabetes Reports, 2011, 11, 47-55.	1.7	40
114	Nebivolol Attenuates Redox-Sensitive Glomerular and Tubular Mediated Proteinuria in Obese Rats. Endocrinology, 2011, 152, 659-668.	1.4	40
115	Biomarkers in diabetic kidney disease. Therapy: Open Access in Clinical Medicine, 2011, 8, 121-127.	0.2	1
116	Indices of Obesity and Cardiometabolic Risk. Hypertension, 2011, 58, 991-993.	1.3	32
117	The Role of Overweight and Obesity in the Cardiorenal Syndrome. CardioRenal Medicine, 2011, 1, 5-12.	0.7	101
118	Overnutrition and the Cardiorenal Syndrome: Use of a Rodent Model to Examine Mechanisms. CardioRenal Medicine, 2011, 1, 23-30.	0.7	16
119	Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program. CardioRenal Medicine, 2011, 1, 45-52.	0.7	17
120	Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study. CardioRenal Medicine, 2011, 1, 53-66.	0.7	9
121	Hypoglycemia: A Possible Link between Insulin Resistance, Metabolic Dyslipidemia, and Heart and Kidney Disease (the Cardiorenal Syndrome). CardioRenal Medicine, 2011, 1, 67-74.	0.7	16
122	The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney. CardioRenal Medicine, 2011, 1, 102-112.	0.7	39
123	The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease. CardioRenal Medicine, 2011, 1, 123-130.	0.7	11
124	Use of Metformin in Patients with Kidney and Cardiovascular Diseases. CardioRenal Medicine, 2011, 1, 87-95.	0.7	29
125	Angiotensin II Activation of mTOR Results in Tubulointerstitial Fibrosis through Loss of N-Cadherin. American Journal of Nephrology, 2011, 34, 115-125.	1.4	40
126	Possible Mechanisms of Local Tissue Renin-Angiotensin System Activation in the Cardiorenal Metabolic Syndrome and Type 2 Diabetes Mellitus. CardioRenal Medicine, 2011, 1, 193-210.	0.7	46

#	Article	IF	Citations
127	Hypertension in Cardiovascular and Kidney Disease. CardioRenal Medicine, 2011, 1, 183-192.	0.7	48
128	A Case for Early Screening for Diabetic Kidney Disease. CardioRenal Medicine, 2011, 1, 235-242.	0.7	3
129	Aldosterone and Risk for Insulin Resistance. Hypertension, 2011, 58, 998-1000.	1.3	12
130	Sex differences in baroreflex sensitivity, heart rate variability, and end organ damage in the TGR(mRen2)27 rat. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H1540-H1550.	1.5	28
131	Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H1484-H1491.	1.5	62
132	Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 301, R885-R895.	0.9	40
133	Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H181-H190.	1.5	17
134	The Role of Oxidative Stress in the Metabolic Syndrome. Reviews in Cardiovascular Medicine, 2011, 12, 21-29.	0.5	113
135	Current Therapy Targeting Oxidative Stress: Statin. , 2011, , 351-366.		0
136	Effect of Age in RAS Activation and Insulin Signaling in the Pancreatic Tissue of db/db Mice. FASEB Journal, 2011, 25, 1063.7.	0.2	0
137	Cytokines in Skeletal Muscle Insulin Resistance. , 2011, , 369-383.		0
138	The importance of early identification of chronic kidney disease. Missouri Medicine, 2011, 108, 25-8.	0.3	8
139	Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. Journal of Molecular Medicine, 2010, 88, 993-1001.	1.7	306
140	The Emerging Role of Biomarkers in Diabetic and Hypertensive Chronic Kidney Disease. Current Diabetes Reports, 2010, 10, 37-42.	1.7	32
141	Cytokine Abnormalities in the Etiology of the Cardiometabolic Syndrome. Current Hypertension Reports, 2010, 12, 93-98.	1.5	48
142	Prevalence of CKD and Comorbid Illness in Elderly Patients in the United States: Results From the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2010, 55, S23-S33.	2.1	230
143	Racial Differences in Kidney Function Among Individuals With Obesity and Metabolic Syndrome: Results From the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2010, 55, S4-S14.	2.1	19
144	Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism: Clinical and Experimental, 2010, 59, 385-389.	1.5	24

#	Article	IF	Citations
145	Aldosterone: Role in the Cardiometabolic Syndrome and Resistant Hypertension. Progress in Cardiovascular Diseases, 2010, 52, 401-409.	1.6	128
146	Dysglycemia Predicts Cardiovascular and Kidney Disease in the Kidney Early Evaluation Program. Journal of Clinical Hypertension, 2010, 12, 51-58.	1.0	29
147	The Effects of Resistance Training on Metabolic Health With Weight Regain. Journal of Clinical Hypertension, 2010, 12, 64-72.	1.0	10
148	Nebivolol Improves Diastolic Dysfunction and Myocardial Remodeling Through Reductions in Oxidative Stress in the Zucker Obese Rat. Hypertension, 2010, 55, 880-888.	1.3	102
149	Micro vs. Macrovascular Reactivity in Insulin Resistance: The Debate Reignited. American Journal of Hypertension, 2010, 23, 458-458.	1.0	0
150	Is there a future for direct renin inhibitors?. Expert Opinion on Investigational Drugs, 2010, 19, 653-661.	1.9	3
151	Gestational Diabetes Mellitus Alone in the Absence of Subsequent Diabetes Is Associated With Microalbuminuria. Diabetes Care, 2010, 33, 2586-2591.	4.3	38
152	Comparative effect of direct renin inhibition and AT₁R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. American Journal of Physiology - Renal Physiology, 2010, 298, F655-F661.	1.3	37
153	Nebivolol Attenuates Maladaptive Proximal Tubule Remodeling in Transgenic Rats. American Journal of Nephrology, 2010, 31, 262-272.	1.4	14
154	Exercise and the metabolic syndrome with weight regain. Journal of Applied Physiology, 2010, 109, 3-10.	1.2	47
155	Should Targeting Albuminuria Be Part of a Cardiovascular Risk Reduction Paradigm?. Cardiology Clinics, 2010, 28, 437-445.	0.9	0
156	Tonsillectomy for the treatment of tonsillitis-induced immunoglobulin A nephropathy. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2010, 31, 485-488.	0.6	4
157	Is it Time to Target Prehypertension. Cardiovascular Therapeutics, 2010, 28, 337-338.	1.1	1
158	CARDIOVASCULAR RISK MODIFICATION IN PARTICIPANTS WITH CORONARY DISEASE SCREENED BY THE KIDNEY EARLY EVALUATION PROGRAM. Internal Medicine Journal, 2010, , .	0.5	1
159	Contribution of oxidative stress to pulmonary arterial hypertension. World Journal of Cardiology, 2010, 2, 316.	0.5	87
160	Effect of Ethnicity on the Progression of Diabetic Kidney Disease Independent of Glycemic Control. American Journal of Nephrology, 2009, 30, 261-267.	1.4	3
161	Nebivolol Reduces Proteinuria and Renal NADPH Oxidase-Generated Reactive Oxygen Species in the Transgenic Ren2 Rat. American Journal of Nephrology, 2009, 30, 354-360.	1.4	55
162	Aspirin and prevention of diabetes still a topic of debate. Nature Reviews Endocrinology, 2009, 5, 365-366.	4.3	1

#	Article	IF	Citations
163	Direct Renin Inhibition Improves Systemic Insulin Resistance and Skeletal Muscle Glucose Transport in a Transgenic Rodent Model of Tissue Renin Overexpression. Endocrinology, 2009, 150, 2561-2568.	1.4	87
164	Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. American Journal of Physiology - Renal Physiology, 2009, 296, F1013-F1022.	1.3	45
165	Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H1184-H1192.	1.5	66
166	Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H1128-H1139.	1.5	26
167	Glycemic control and cardiovascular disease in a high-risk chronic kidney disease population. Therapy: Open Access in Clinical Medicine, 2009, 6, 507-513.	0.2	1
168	Low Aerobic Capacity and High-Fat Diet Contribute to Oxidative Stress and IRS-1 Degradation in the Kidney. American Journal of Nephrology, 2009, 30, 112-119.	1.4	18
169	Mineralocorticoid Receptor Antagonism Attenuates Vascular Apoptosis and Injury via Rescuing Protein Kinase B Activation. Hypertension, 2009, 53, 158-165.	1.3	42
170	Hypertension and Insulin Resistance. Hypertension, 2009, 54, 462-464.	1.3	41
171	Nebivolol in Obese and Nonâ€Obese Hypertensive Patients. Journal of Clinical Hypertension, 2009, 11, 309-315.	1.0	24
172	Reninâ€Angiotensinâ€Aldosterone System Inhibition and Improvement in Glucose Tolerance. Journal of Clinical Hypertension, 2009, 11, .	1.0	1
173	Diabetes Mellitus and CKD Awareness: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). American Journal of Kidney Diseases, 2009, 53, S11-S21.	2.1	95
174	Dual renin-angiotensin system blockade in the ONTARGET study: Clinically relevant risk for the kidney?. Current Hypertension Reports, 2009, 11, 375-381.	1.5	2
175	Inhibition of nitric oxide synthase evokes central sympathoâ€excitation in healthy humans. Journal of Physiology, 2009, 587, 4977-4986.	1.3	51
176	Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease. Translational Research, 2009, 153, 102-113.	2.2	31
177	Oxidative Stress-Mediated Mitochondrial Dysfunction Contributes to Angiotensin II-Induced Nonalcoholic Fatty Liver Disease in Transgenic Ren2 Rats. American Journal of Pathology, 2009, 174, 1329-1337.	1.9	56
178	Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant Hypertension. Annals of Internal Medicine, 2009, 150, 776.	2.0	309
179	Exercise And The Metabolic Syndrome With Weight Regain. Medicine and Science in Sports and Exercise, 2009, 41, 523.	0.2	1
180	Mineralocorticoid Receptor (MR) Inhibition Attenuates High Saltâ€Aldosterone Induced Increases in Vascular Reninâ€Angiotensinâ€Aldoesterone System (RAAS) and Oxidative Stress. FASEB Journal, 2009, 23, 626.18.	0.2	0

#	Article	IF	Citations
181	Direct renin inhibition with Aliskiren lowers blood pressure and improves renal dysfunction in Ren2 rats. FASEB Journal, 2009, 23, 606.13.	0.2	0
182	Rosuvastatin Attenuates Pulmonary Arterial Hypertension in the Transgenic (mREN2)27 (Ren2) Rat. FASEB Journal, 2009, 23, 770.4.	0.2	0
183	Mineralcorticoid Receptor (MR) Antagonism Attenuates Glomerular Filtration Barrier Remodeling in the Transgenic Ren2 Rat. FASEB Journal, 2009, 23, 803.16.	0.2	0
184	Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vascular Health and Risk Management, 2009, 5, 129-40.	1.0	26
185	Antihypertensive medications and their effects on lipid metabolism. Current Diabetes Reports, 2008, 8, 214-220.	1.7	19
186	The cardiometabolic syndrome and chronic kidney disease. Current Cardiovascular Risk Reports, 2008, 2, 95-100.	0.8	0
187	Diabetes Mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004. American Journal of Kidney Diseases, 2008, 51, S21-S29.	2.1	47
188	CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. American Journal of Kidney Diseases, 2008, 51, S13-S20.	2.1	162
189	CKD and Cardiovascular Disease in Screened High-Risk Volunteer and General Populations: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. American Journal of Kidney Diseases, 2008, 51, S38-S45.	2.1	141
190	Trends in Mineral Metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. American Journal of Kidney Diseases, 2008, 51, S56-S68.	2.1	60
191	Prevalence and Associations of Anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. American Journal of Kidney Diseases, 2008, 51, S46-S55.	2.1	95
192	CKD Awareness in the United States: The Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2008, 52, 382-383.	2.1	42
193	Attenuation of Endocrineâ€Exocrine Pancreatic Communication in Type 2 Diabetes: Pancreatic Extracellular Matrix Ultrastructural Abnormalities. Journal of the Cardiometabolic Syndrome, 2008, 3, 234-243.	1.7	61
194	Aldosterone and Hypertension in the Cardiometabolic Syndrome. Journal of Clinical Hypertension, 2008, 10, 94-96.	1.0	12
195	Chronic kidney disease as a cardiovascular risk state and considerations for the use of statins. Journal of Clinical Lipidology, 2008, 2, 318-327.	0.6	3
196	Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. Journal of Hepatology, 2008, 49, 417-428.	1.8	101
197	Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. American Heart Journal, 2008, 156, 277-283.	1.2	160
198	Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 294, R673-R680.	0.9	204

#	Article	IF	Citations
199	Outcomes of Carotid Revascularization in Patients With Chronic Kidney Disease. Advances in Chronic Kidney Disease, 2008, 15, 347-354.	0.6	2
200	Redox Control of Renal Function and Hypertension. Antioxidants and Redox Signaling, 2008, 10, 2047-2089.	2.5	140
201	Obesity, Insulin Resistance, and Nocturnal Systolic Blood Pressure. Hypertension, 2008, 51, 620-621.	1.3	8
202	Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E110-E116.	1.8	102
203	Effect of renin inhibition and AT₁R blockade on myocardial remodeling in the transgenic Ren2 rat. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E103-E109.	1.8	50
204	Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H2659-H2668.	1.5	69
205	Attenuation of NADPH Oxidase Activation and Glomerular Filtration Barrier Remodeling With Statin Treatment. Hypertension, 2008, 51, 474-480.	1.3	90
206	Renin Inhibition Attenuates Insulin Resistance, Oxidative Stress, and Pancreatic Remodeling in the Transgenic Ren2 Rat. Endocrinology, 2008, 149, 5643-5653.	1.4	69
207	Insulin Resistance, Oxidative Stress, and Podocyte Injury: Role of Rosuvastatin Modulation of Filtration Barrier Injury. American Journal of Nephrology, 2008, 28, 67-75.	1.4	45
208	Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vascular Health and Risk Management, 2008, , 129.	1.0	20
209	Rosuvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Decreases Cardiac Oxidative Stress and Remodeling in Ren2 Transgenic Rats. Endocrinology, 2007, 148, 2181-2188.	1.4	67
210	Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. American Journal of Physiology - Renal Physiology, 2007, 292, F861-F867.	1.3	28
211	Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E355-E363.	1.8	84
212	Mineralocorticoid Receptor Blockade Attenuates Chronic Overexpression of the Renin-Angiotensin-Aldosterone System Stimulation of Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Cardiac Remodeling. Endocrinology, 2007, 148, 3773-3780.	1.4	96
213	Albumin Activation of NAD(P)H Oxidase Activity Is Mediated via Rac1 in Proximal Tubule Cells. American Journal of Nephrology, 2007, 27, 15-23.	1.4	61
214	Obesity and chronic kidney disease: therapeutic implications. Therapy: Open Access in Clinical Medicine, 2007, 4, 585-595.	0.2	1
215	NADPH Oxidase Contributes to Vascular Inflammation, Insulin Resistance, and Remodeling in the Transgenic (mRen2) Rat. Hypertension, 2007, 50, 384-391.	1.3	100
216	Chronic kidney disease and cardiovascular risk. Journal of the American Society of Hypertension, 2007, 1, 178-184.	2.3	24

#	Article	IF	Citations
217	Review: Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification. Therapeutic Advances in Cardiovascular Disease, 2007, 1, 107-112.	1.0	3
218	Review: Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. Therapeutic Advances in Cardiovascular Disease, 2007, 1, 27-35.	1.0	19
219	Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2009-H2023.	1.5	248
220	Hypertension in people with diabetes and the metabolic syndrome: Pathophysiologic insights and therapeutic update. Current Diabetes Reports, 2007, 7, 208-217.	1.7	13
221	Overexpression of the Tissue Reninâ€Angiotensin System Causes Pulmonary Hypertension (PH) in TG(mRen2)27 Rat. FASEB Journal, 2007, 21, A1252.	0.2	0
222	Diabetic Hypertension. Heart Failure Clinics, 2006, 2, 25-36.	1.0	4
223	Chronic Kidney Disease and the Cardiometabolic Syndrome. Journal of Clinical Hypertension, 2006, 8, 546-548.	1.0	3
224	Role of angiotensin II in diabetic cardiovascular and renal disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2006, 13, 135-140.	0.6	7
225	Obesity and Insulin Resistance As Risk Factors for Chronic Kidney Disease. Journal of the Cardiometabolic Syndrome, 2006, 1, 209-216.	1.7	24
226	Cardiometabolic Syndrome and Chronic Kidney Disease: What Is the Link?. Journal of the Cardiometabolic Syndrome, 2006, 1, 58-65.	1.7	43
227	Hyponatremia, Arginine Vasopressin Dysregulation, and Vasopressin Receptor Antagonism. American Journal of Nephrology, 2006, 26, 579-589.	1.4	42
228	Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. American Journal of Physiology - Renal Physiology, 2006, 291, F1308-F1314.	1.3	99
229	Hypertension and Cardiovascular Disease. , 2006, , 499-513.		4
230	The Cardiometabolic Syndrome as a Cardiovascular Risk Factor. American Journal of the Medical Sciences, 2005, 330, 311-318.	0.4	68
231	The Key Role of Insulin Resistance in the Cardiometabolic Syndrome. American Journal of the Medical Sciences, 2005, 330, 290-294.	0.4	58
232	Renal Redox Stress and Remodeling in Metabolic Syndrome, Type 2 Diabetes mellitus, and Diabetic Nephropathy: Paying Homage to the Podocyte. American Journal of Nephrology, 2005, 25, 553-569.	1.4	74
233	Insights into the emerging cardiometabolic prevention and management of diabetes mellitus. Expert Opinion on Pharmacotherapy, 2005, 6, 2209-2221.	0.9	16
234	Hypertension and the Cardiometabolic Syndrome. Journal of Clinical Hypertension, 2005, 7, 471-476.	1.0	56

#	Article	IF	Citations
235	Hypertension Management in Type 2 Diabetes Mellitus: Recommendations of the Joint National Committee VII. Endocrinology and Metabolism Clinics of North America, 2005, 34, 63-75.	1.2	22
236	Rates of continuous ambulatory peritoneal dialysis-associated peritonitis at the University of Missouri. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2005, 21, 72-5.	0.1	10
237	Recommendations for Special Populations. , 2004, 14, 368-381.		8
238	Meal Frequency Differentially Alters Postprandial Triacylglycerol and Insulin Concentrations in Obese Women. Obesity, 0, , .	1.5	2